Data as of Nov 4, 2026.
PCOV vs TPRY: Dividend Yield & Total Return
PCOV and TPRY both write options for income.
askIQ about this page
askIQ about PCOV and TPRY
Net assets: $10m on Nov 2, 2026 for Principal Equity Premium Income ETF, and $3.3m on Nov 3, 2026 for VistaShares Target 15 TEPRTantrum Contrarian Distribution ETF.
Not measured
PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
PCOV
−0.1%
Total return, distributions reinvested
Not measured
PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
PCOV
−0.1%
1.9% of it arrived as cash. Total return, distributions reinvested. PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
Data to Nov 4, 2026.19.3 pts behind SPY
TPRY since launch: paid 9.7%, price −16.1%, total −7.2%, SPY +12.1%, −19.3 pts. Data to Nov 4, 2026.
SPY
+12.1%
TPRY
−7.2%
19.3 pts behind SPY
Total return, distributions reinvested
19.3 pts behind SPY
TPRY since launch: paid 9.7%, price −16.1%, total −7.2%, SPY +12.1%, −19.3 pts. Data to Nov 4, 2026.
SPY
+12.1%
TPRY
−7.2%
19.3 pts behind SPY
9.7% of it arrived as cash. Both charts share one scale, with zero at the line. TPRY since launch: paid 9.7%, price −16.1%, total −7.2%, SPY +12.1%, −19.3 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
PCOV costs 0.61 points a year less; PCOV is 3.0 times larger.
Points (pts) are percentage points.
| Measure | PCOV | TPRY |
|---|---|---|
| Paid and earned | ||
| Price change | fell 2.0% (since Aug 19, 2026) | fell 16.1% (since Feb 26, 2026) |
| Return of capital, issuer estimate | 19% of the Oct 27, 2026 payment | |
| Against its benchmark | ||
| Benchmark | not published | S&P 500, measured through SPY |
| Cost and size | ||
| Expense ratio | 0.34% | 0.95% |
| Net assets, as of Nov 3, 2026 | $10m | $3.3m |
| Holdings | ||
| Holdings in common | not published | |
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | PCOV | TPRY | PCOV | TPRY | PCOV | TPRY |
| 3 months | – | −9.7% | – | 3.6% | – | −9.5 pts |
| 6 months | – | −14.1% | – | 6.9% | – | −19.1 pts |
| Since launchNot the same days: PCOV Aug 2026 · TPRY Feb 2026 | −0.1% | −7.2% | 1.9% | 9.7% | not measured | −19.3 pts |
– means no data for this window. Open this comparison in the app →
PCOV
Over the period from its first trade on Aug 19, 2026 to Nov 4, 2026, PCOV paid 1.9% of its starting value in cash distributions while its price fell 2.0%. With every distribution reinvested, the fund returned −0.1%. At its price on Nov 4, 2026 the latest distribution annualizes to 7.2%, paid periodically.
TPRY
Over the period from its first trade on Feb 26, 2026 to Nov 4, 2026, TPRY paid 9.7% of its starting value in cash distributions while its price fell 16.1%. With every distribution reinvested, the fund returned −7.2%. S&P 500 (SPY) returned +12.1% over the same days, so a holder was behind by 19.3 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 15.7%, paid monthly. VistaShares estimates that 19% of the distribution paid Oct 27, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, PCOV against TPRY, data as of Nov 4, 2026. https://etfiq.com/compare/income/pcov-vs-tpry
ETFIQ. (Nov 4, 2026). PCOV against TPRY. Retrieved from https://etfiq.com/compare/income/pcov-vs-tpry
[PCOV against TPRY (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/pcov-vs-tpry)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.